Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Fineline Cube Mar 23, 2026
Company Deals

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Fineline Cube Mar 23, 2026
Company Deals Drug

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Fineline Cube Mar 23, 2026
Company Deals

Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36

Fineline Cube Mar 20, 2026
Company Deals Medical Device

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Fineline Cube Mar 19, 2026
Policy / Regulatory

China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices

Fineline Cube Mar 23, 2026
Company Drug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Fineline Cube Mar 23, 2026
Company Drug

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Fineline Cube Mar 23, 2026
Policy / Regulatory

China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes

Fineline Cube Jan 17, 2024

The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC

Fineline Cube Jan 17, 2024

The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...

Company Drug

Changchun High & New Technology Industries to Launch GenSci125 Phase I Trial in US

Fineline Cube Jan 17, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading Chinese pharmaceutical company,...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Approval for Phase II Cervical Cancer Study

Fineline Cube Jan 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Drug

Roche’s Tecentriq SC Receives European Nod as First Subcutaneous PD-(L)1 Therapy

Fineline Cube Jan 17, 2024

Halozyme Therapeutics (NASDAQ: HALO) has announced that the European Commission (EC) has granted marketing authorization...

Company Drug

Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China

Fineline Cube Jan 17, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of...

Company Deals

Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals

Fineline Cube Jan 17, 2024

Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans...

Company Drug

Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China

Fineline Cube Jan 17, 2024

Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has...

Company Deals

China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers

Fineline Cube Jan 17, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi...

Company Deals

Wuhan EasyDiagnosis Biomedicine Partners with Ailex Technology Group for Global Glycated Hemoglobin Testing Market

Fineline Cube Jan 17, 2024

Wuhan EasyDiagnosis Biomedicine Co., Ltd (SHE: 002932), a Chinese biomedicine company, has announced a strategic...

Company Drug

RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China

Fineline Cube Jan 17, 2024

RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...

Company Legal / IP

WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent

Fineline Cube Jan 17, 2024

WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...

Company Drug

Drug Farm’s DF-003 Earns FDA Rare Pediatric Disease Designation for ROSAH Syndrome

Fineline Cube Jan 17, 2024

Sino-US biotech company Drug Farm has announced that it has received Rare Pediatric Disease Designation...

Company Deals

SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China

Fineline Cube Jan 17, 2024

SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces...

Company Deals

Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution

Fineline Cube Jan 17, 2024

Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based...

Company Deals

XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China

Fineline Cube Jan 17, 2024

Sino-US AI drug development company XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...

Company Drug

InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248

Fineline Cube Jan 17, 2024

InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has...

Company Drug

Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001

Fineline Cube Jan 17, 2024

China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...

Company Deals

Mindray Partners with WakeMed for Comprehensive Patient Monitoring Solutions

Fineline Cube Jan 16, 2024

Shenzhen-based medtech company Mindray has announced a procurement agreement with WakeMed Health & Hospitals in...

Company Drug

3D Medicines Secures Registration for Envafolimab in Macau for Advanced Solid Tumors

Fineline Cube Jan 16, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1...

Posts pagination

1 … 386 387 388 … 638

Recent updates

  • Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push
  • Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China
  • Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China
  • Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic
  • Henlius Biotech Reports 2025 Revenue Growth 16.5% – Ex‑China Business Doubles as Global Expansion Accelerates
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Company Drug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Company Deals

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Company Drug

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.